^
Association details:
| Biomarker: | JAK2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Excerpt:
...Maximum Tolerated Dose of Ruxolitinib Phosphate (Phase I)`Number of Participants With a Response (Complete Response [CR] + CR With Incomplete Blood Count Recovery) (Phase 2)`Number of Participants With Post-MPN Acute Myeloid Leukemia (AML) With JAK2 Mutations (Phase 2)...
Trial ID:
Source:
Title:
An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML Eine offene, multizentrische Studie mit INC424 als Monotherapie oder in Kombination mit Azacitidin für Patienten mit AML (akute myeloische Leukämi) als Folge einer myeloproliferativen Erkrankung oder mit CMML (chronische myelomonozytäre Leukämie)
Excerpt:
...Patients must be diagnosed with postmyeloproliferative AML according to the 2008 World Health Organization criteria (Appendix A), irrespective of JAK2 mutation status or diagnosed with CMML with a white-blood-cell count above 13×10⁹ cells /L.2. ...
Trial ID:
Less C2 evidence
Source:
Title:
Molecular targeted therapy in acute myeloid leukemia
Excerpt:
18 patients with relapsed and refractory leukemias... were treated with ruxolitinib....Three patients (including two with sAML and one with CMML, all with JAK2 mutation) had significant declines in their bone marrow blasts (to <5%) and clinical improvement.
DOI:
https://doi.org/10.1179/102453312X13336169155619
